It has been proposed that the neurological abnormalities of Parkinsonism can be divided into positive and negative symptoms (Martin, 1967) . Positive symptoms are considered to be release phenomena. Pathological changes within one region of the central nervous system result in the release of this region's control over a second region. The positive symptoms are felt to be related to the physiological dysfunction in this second region. This results from the loss of the normal inhibition of this structure. Examples of positive symptoms are tremor and rigidity.
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Negative symptoms are thought to be due to disease of a structure resulting in loss of its normal function. Negative symptoms include difficulty with postural fixation and righting reflexes and akinesia. In humans with Parkinsonism, it has been proposed that 'the degree of damage in the pallidum is sufficient to account for all the loss of postural reflexes' (Martin, 1967) .
The purpose of this communication is to review the validity and usefulness of the above classification of symptoms in relation to clinical investigations with the drug L-dopa. PHARMACOLOGY L-Dopa (L-3, 4-dihydroxyphenylalanine) is the immediate precursor of dopamine. Dopamine is the predominant catecholamine in the basal ganglia and substantia nigra (Sano, Gamo, Kakimoto, Taniguchi, Jakesada, and Nishinuma, 1959) . In most species dopamine acts as predominantly inhibitory neurotransmitter (Hornykiewicz, 1966 
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formed on the dopaminergic receptors (Barbeau, 1962; Klawans, 1968 
METHODS
Patients with known Parkinsonism were hospitalized and taken off standard anti-Parkinsonism medication. Each was begun on 1 to 4 g oral L-dopa daily and increased to the maintenance dose of 4 to 6 g daily over a two-week period. The rate of increase and total dose varied according to patient tolerance and response. Motion pictures were taken of all patients before and during L-dopa therapy. Judgements of postural stability were based on the patient's response to a sudden posterior displacement produced by a push on the sternum with the patient standing as erect as possible. Judgements were made by one of us (H.K.) on reviewing the motion pictures randomly without knowledge as to whether the patient in any movie had yet received L-dopa. Responses were graded as follows: (0) = normal;
(1) = retropulsion but recovers unaided; (2) = retropulsion but does not recover unaided; (3) = absence of postural response-would fall if not caught by attendant; (4) = very unstable-tends to fall spontaneously or on turning; (5) = unable to stand without assistance.
RESULTS
The results of this experiment are shown in the Table. As evaluated by the sign test, the probability of observing 15 patients with improvement (positive difference) and none with worsening (negative difference) is less than 0-001. Similarly, Student's t test is also significant with a level of confidence of over 0-001.
The overall results of therapy in these patients will be presented in the future.
L-Dopa and the negative symptoms ofParkinsonism The above data demonstrate striking improvement in a negative symptom of Parkinsonism, brought about by L-dopa therapy. This result casts doubt on the validity of the present concept of positive and negative symptoms in Parkinsonism and on the one relationship of negative symptoms to destructive lesions. It raises the possibility that so-called negative symptoms are also related to a loss of inhibition or at least to a mechanism that can be reversed by increased central dopamine inhibition.
The observations in this recording relate only to postural reflexes. This symptom was studied because it is the negative symptom whose theoretical pathogenesis and direct relationship to destructive lesions has been best studied. It should also be noted that akinesia which has been suggested to be a negative symptom also responds to L-dopa (Cotzias etal., 1969 
